WO2003060078A8 - Heterocyclic modulators of nuclear receptors - Google Patents
Heterocyclic modulators of nuclear receptorsInfo
- Publication number
- WO2003060078A8 WO2003060078A8 PCT/US2002/041224 US0241224W WO03060078A8 WO 2003060078 A8 WO2003060078 A8 WO 2003060078A8 US 0241224 W US0241224 W US 0241224W WO 03060078 A8 WO03060078 A8 WO 03060078A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nuclear receptors
- heterocyclic modulators
- compounds
- heterocyclic
- modulating
- Prior art date
Links
- 108020005497 Nuclear hormone receptor Proteins 0.000 title abstract 2
- 102000006255 nuclear receptors Human genes 0.000 title abstract 2
- 108020004017 nuclear receptors Proteins 0.000 title abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 102100038495 Bile acid receptor Human genes 0.000 abstract 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004311 liver X receptors Human genes 0.000 abstract 2
- 108090000865 liver X receptors Proteins 0.000 abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004164 orphan nuclear receptors Human genes 0.000 abstract 1
- 108090000629 orphan nuclear receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT02806505T ATE521599T1 (en) | 2001-12-21 | 2002-12-20 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS |
EP02806505A EP1465882B1 (en) | 2001-12-21 | 2002-12-20 | Hetrocyclic modulators of nuclear receptors |
AU2002367060A AU2002367060A1 (en) | 2001-12-21 | 2002-12-20 | Heterocyclic modulators of nuclear receptors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34272001P | 2001-12-21 | 2001-12-21 | |
US60/342,720 | 2001-12-21 |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2003060078A2 WO2003060078A2 (en) | 2003-07-24 |
WO2003060078A9 WO2003060078A9 (en) | 2004-02-19 |
WO2003060078A8 true WO2003060078A8 (en) | 2004-04-29 |
WO2003060078A3 WO2003060078A3 (en) | 2004-06-24 |
Family
ID=23342988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/041224 WO2003060078A2 (en) | 2001-12-21 | 2002-12-20 | Heterocyclic modulators of nuclear receptors |
Country Status (6)
Country | Link |
---|---|
US (2) | US6696473B2 (en) |
EP (1) | EP1465882B1 (en) |
AT (1) | ATE521599T1 (en) |
AU (1) | AU2002367060A1 (en) |
ES (1) | ES2367539T3 (en) |
WO (1) | WO2003060078A2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001016122A1 (en) * | 1999-08-31 | 2001-03-08 | Maxia Pharmaceuticals, Inc. | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
US6696473B2 (en) * | 2001-12-21 | 2004-02-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
US20040259948A1 (en) * | 2003-01-10 | 2004-12-23 | Peter Tontonoz | Reciprocal regulation of inflammation and lipid metabolism by liver X receptors |
WO2004113533A1 (en) * | 2003-06-24 | 2004-12-29 | Sumitomo Chemical Company, Limited | LIVER X RECEPTOR α SPLICING VARIANT PROTEIN, GENE CODING FOR THE SAME AND USE THEREOF |
US7341850B2 (en) | 2003-08-18 | 2008-03-11 | Wyeth | Human LXRα variants |
AU2005272916A1 (en) * | 2004-08-10 | 2006-02-23 | Exelixis, Inc. | Heterocyclic compounds as pharmaceutical agents |
JP4553355B2 (en) * | 2004-10-04 | 2010-09-29 | 富士フイルム株式会社 | Pharmaceutical composition for prevention or treatment of Trypanosoma protozoan parasitic infection |
US7618956B2 (en) * | 2005-05-31 | 2009-11-17 | The Gillette Company | Reduction of hair growth |
WO2009009139A2 (en) * | 2007-07-11 | 2009-01-15 | The General Hospital Corporation | Rna ligase polypeptides and methods of selection and use thereof |
US20100113581A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100113604A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
WO2010045417A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100113583A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
WO2010045522A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100331419A1 (en) * | 2009-06-25 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
WO2010151565A2 (en) * | 2009-06-26 | 2010-12-29 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100331999A1 (en) * | 2009-06-29 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20110015663A1 (en) * | 2009-07-17 | 2011-01-20 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20110082407A1 (en) * | 2009-10-01 | 2011-04-07 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
AU2011299703A1 (en) | 2010-09-07 | 2013-04-11 | Snu R&Db Foundation | Sesterterpene compounds and use thereof |
CN110404073B (en) | 2013-09-11 | 2022-08-16 | 国家医疗保健研究所 | Methods and pharmaceutical compositions for treating hepatitis B virus infection |
WO2015106164A1 (en) | 2014-01-10 | 2015-07-16 | Rgenix, Inc. | Lxr agonists and uses thereof |
WO2016198908A1 (en) | 2015-06-09 | 2016-12-15 | Abbvie Inc. | Ror nuclear receptor modulators |
WO2017123568A2 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
JP2020515564A (en) | 2017-03-30 | 2020-05-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Methods and pharmaceutical compositions for reducing episomal virus persistence and expression |
AU2018344370C1 (en) | 2017-10-04 | 2023-04-27 | Bayer Aktiengesellschaft | Derivatives of heterocyclic compounds as pest control agents |
CA3078981A1 (en) | 2017-11-21 | 2019-05-31 | Rgenix, Inc. | Polymorphs and uses thereof |
JP2023509845A (en) | 2019-12-13 | 2023-03-10 | インスピルナ,インコーポレーテッド | Metal salt and its use |
CN111041014B (en) * | 2019-12-31 | 2022-03-18 | 浙江工业大学 | Magnetic immobilized lipase and application thereof in resolution of 1-methyl-3-amphetamine |
CN113181160A (en) * | 2020-01-14 | 2021-07-30 | 无锡杰西医药股份有限公司 | Application of isothiocyanate compounds |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US132223A (en) * | 1872-10-15 | Improvement in bale-ties | ||
US120137A (en) * | 1871-10-17 | Improvement in mill-bolts | ||
US228607A (en) * | 1880-06-08 | Door-hanger | ||
US181420A (en) * | 1876-08-22 | Improvement in stove-platforms | ||
GB489335A (en) | 1937-01-22 | 1938-07-22 | Douglas James Fry | Improvements in or relating to the manufacture and use of dyestuffs suitable for sensitising photographic emulsions |
US2454629A (en) | 1940-01-27 | 1948-11-23 | Eastman Kodak Co | Polymethine dyes |
FR1449800A (en) | 1964-07-02 | 1966-05-06 | Kodak Pathe | New chromatic sensitizing dyes |
CA918992A (en) | 1968-02-21 | 1973-01-16 | Tsubota Motohiko | Direct positive photographic emulsion |
US3635964A (en) | 1969-02-10 | 1972-01-18 | Colgate Palmolive Co | 5-morpholinyl-2 1-benzisothiazolines |
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
FR2117337A5 (en) | 1970-12-04 | 1972-07-21 | Eastman Kodak Co | Merocyanine dye sensitisers - contg basic and acidic gps for silver halide emulsions |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
IT1039699B (en) | 1975-07-03 | 1979-12-10 | Prephar | SPERMICIDE COMPOSITION BASED ON BENZISOTHIAZOLIC DERIVATIVES |
JPS53129633A (en) | 1977-04-19 | 1978-11-11 | Fuji Photo Film Co Ltd | Silver halide photographic material |
US4258185A (en) | 1978-10-17 | 1981-03-24 | Yoshitomi Pharmaceutical Industries, Ltd. | Pyridazinone compounds |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (en) | 1980-06-06 | 1986-07-28 | Sankyo Co | METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
WO1984002131A1 (en) | 1982-11-22 | 1984-06-07 | Sandoz Ag | Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4721721A (en) | 1984-12-18 | 1988-01-26 | Rorer Pharmaceutical Corporation | 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
US5221623A (en) | 1986-07-22 | 1993-06-22 | Boyce Thompson Institute For Plant Research, Inc. | Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms |
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
AU614965B2 (en) | 1987-06-06 | 1991-09-19 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Thiadiazinones |
EP0303418A3 (en) | 1987-08-11 | 1990-11-07 | Smithkline Beecham Laboratoires Pharmaceutiques | Substituted indolones, useful in the treatment of heart or asthmatic diseases |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5070012A (en) | 1988-03-30 | 1991-12-03 | The Board Of Trustees Of The Leland Stanford Junior University | Monitoring of cells and trans-activating transcription elements |
FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
DE3932953A1 (en) | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | NEW 2-BICYCLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
KR0164842B1 (en) | 1990-03-24 | 1999-01-15 | 손정삼 | Novel benzoxazine, benzothiazine derivatives and preparation thereof |
TW203049B (en) | 1990-04-13 | 1993-04-01 | Yamanouchi Pharma Co Ltd | |
US5283179A (en) | 1990-09-10 | 1994-02-01 | Promega Corporation | Luciferase assay method |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
EP0510235A1 (en) | 1991-04-26 | 1992-10-28 | Dong-A Pharm. Co., Ltd. | Novel benzoxazine or benzothiazine derivatives and process for the preparation of the same |
JPH0527356A (en) | 1991-07-23 | 1993-02-05 | Konica Corp | Spectrally sensitized silver halide photographic sensitive material |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
JPH0620053A (en) | 1992-07-03 | 1994-01-28 | Sankyo Seiki Mfg Co Ltd | Pattern recognizing method |
JP2879395B2 (en) * | 1992-10-26 | 1999-04-05 | 富士写真フイルム株式会社 | Anticancer composition containing rhodacyanine compound and cyclodextrin |
US5618831A (en) * | 1992-11-17 | 1997-04-08 | Fuji Photo Film Co., Ltd. | Composition and method for treating cancer |
US5476945A (en) * | 1992-11-17 | 1995-12-19 | Fuji Photo Film Co., Ltd. | Water-soluble methine derivatives of thiazole |
JPH06234639A (en) * | 1993-02-10 | 1994-08-23 | Fuji Photo Film Co Ltd | Immunosuppressant |
FR2707120B1 (en) | 1993-07-02 | 1995-09-22 | Lectra Systemes Sa | Clothes grading system. |
EP0743520A3 (en) | 1993-12-30 | 1999-11-10 | The Salk Institute For Biological Studies | Novel uses for GAL4-receptor constructs |
JP3466765B2 (en) | 1994-07-27 | 2003-11-17 | キッコーマン株式会社 | Biotinylated firefly luciferase, biotinylated firefly luciferase gene, novel recombinant DNA, method for producing biotinylated firefly luciferase and bioluminescence analysis method |
US6005086A (en) | 1995-01-13 | 1999-12-21 | The Salk Institute For Biological Studies | Farnesoid activated receptor polypeptides, and nucleic acid encoding the same |
US5741657A (en) | 1995-03-20 | 1998-04-21 | The Regents Of The University Of California | Fluorogenic substrates for β-lactamase and methods of use |
AUPN449295A0 (en) * | 1995-07-28 | 1995-08-24 | Inner And Eastern Health Care Network, The | Radioprotectors |
DE69627355T2 (en) | 1995-08-18 | 2004-02-12 | Auckland Uniservices Ltd. | CYTOTOXIN THERAPY ACTIVATED BY RADIATION |
US5955604A (en) | 1996-10-15 | 1999-09-21 | The Regents Of The University Of California | Substrates for β-lactamase and uses thereof |
US5707794A (en) | 1996-11-22 | 1998-01-13 | Sterling Diagnostic Imaging, Inc. | Spectral sensitization of silver halide photographic elements |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
BR9806989A (en) | 1997-01-24 | 2000-03-14 | Univ California | Process for treating the epidermis or mucous membrane of a mammalian individual. |
US7101681B1 (en) | 1997-11-21 | 2006-09-05 | Amgen, Inc. | Nuclear hormone receptor drug screens |
MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
EP0985683A1 (en) | 1998-09-09 | 2000-03-15 | Fuji Photo Film Co., Ltd. | Photosensitive composition and method for manufacturing lithographic printing plate |
EP1115853A2 (en) | 1998-09-23 | 2001-07-18 | Ludmila Solomin | Analysis of ligand activated nuclear receptors in vivo |
AU1229000A (en) | 1998-10-23 | 2000-05-15 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
WO2000037077A1 (en) | 1998-12-23 | 2000-06-29 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
WO2000040965A1 (en) | 1999-01-07 | 2000-07-13 | Tularik, Inc. | Fxr receptor-mediated modulation of cholesterol metabolism |
SK10032001A3 (en) | 1999-01-14 | 2002-05-09 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
US6071955A (en) | 1999-02-25 | 2000-06-06 | The Regents Of The University Of California | FXR, PPARA and LXRA activators to treat acne/acneiform conditions |
US6291676B1 (en) | 1999-03-03 | 2001-09-18 | University Of Kentucky Research Foundation | Water-soluble derivatives of camptothecin/homocamptothecin |
EP1165135B1 (en) | 1999-03-26 | 2004-09-01 | City of Hope | Methods of screening for compounds modulating fxr receptors |
US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
US6316510B1 (en) | 1999-04-13 | 2001-11-13 | Henry Sperber | Foamable binder composition and methods for producing the same |
JP2003501418A (en) * | 1999-06-04 | 2003-01-14 | エラン ファーマ インターナショナル,リミティド | Compositions and methods for inhibiting cell death |
US6452032B1 (en) | 1999-06-11 | 2002-09-17 | Allergan Sales, Llc | Organosilyl compounds having nuclear hormone receptor modulating activity |
CN1368884A (en) | 1999-06-11 | 2002-09-11 | 阿勒根销售公司 | Method for modulating FXR receptor activity |
CA2375781A1 (en) | 1999-06-18 | 2000-12-28 | Cv Therapeutics, Inc. | Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abci |
JP2001013617A (en) | 1999-06-29 | 2001-01-19 | Konica Corp | Silver halide emulsion, silver halide photosensitive material and heat developable photosensitive material |
WO2001017994A1 (en) | 1999-09-08 | 2001-03-15 | Glaxo Group Limited | Oxazole ppar antagonists |
GB2354304A (en) | 1999-09-16 | 2001-03-21 | Barrus Ltd E P | A valve and a marine propulsion unit incorporating a valve |
US6458789B1 (en) | 1999-09-29 | 2002-10-01 | Lion Bioscience Ag | 2-aminopyridine derivatives and combinatorial libraries thereof |
WO2001060818A1 (en) | 2000-02-14 | 2001-08-23 | Tularik Inc. | Lxr modulators |
US6586453B2 (en) * | 2000-04-03 | 2003-07-01 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
US20020048572A1 (en) | 2000-05-03 | 2002-04-25 | Bei Shan | Treatment of hypertriglyceridemia and other conditions using LXR modulators |
GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
AU2001288623A1 (en) | 2000-09-05 | 2002-03-22 | Tularik, Inc. | Fxr modulators |
PL365443A1 (en) * | 2001-01-31 | 2005-01-10 | Pfizer Products Inc. | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
US6696473B2 (en) * | 2001-12-21 | 2004-02-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
WO2003059884A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
US20030228607A1 (en) | 2002-04-15 | 2003-12-11 | Wagner Brandee Lynn | Screening method and modulators having an improved therapeutic profile |
-
2002
- 2002-12-20 US US10/329,668 patent/US6696473B2/en not_active Expired - Lifetime
- 2002-12-20 EP EP02806505A patent/EP1465882B1/en not_active Expired - Lifetime
- 2002-12-20 ES ES02806505T patent/ES2367539T3/en not_active Expired - Lifetime
- 2002-12-20 AT AT02806505T patent/ATE521599T1/en not_active IP Right Cessation
- 2002-12-20 WO PCT/US2002/041224 patent/WO2003060078A2/en not_active Application Discontinuation
- 2002-12-20 AU AU2002367060A patent/AU2002367060A1/en not_active Abandoned
-
2003
- 2003-11-18 US US10/717,049 patent/US7115640B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20040180942A1 (en) | 2004-09-16 |
AU2002367060A1 (en) | 2003-07-30 |
EP1465882A2 (en) | 2004-10-13 |
ATE521599T1 (en) | 2011-09-15 |
WO2003060078A3 (en) | 2004-06-24 |
US20030212111A1 (en) | 2003-11-13 |
AU2002367060A8 (en) | 2003-07-30 |
EP1465882B1 (en) | 2011-08-24 |
US7115640B2 (en) | 2006-10-03 |
WO2003060078A2 (en) | 2003-07-24 |
WO2003060078A9 (en) | 2004-02-19 |
ES2367539T3 (en) | 2011-11-04 |
EP1465882A4 (en) | 2005-04-06 |
US6696473B2 (en) | 2004-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003060078A3 (en) | Heterocyclic modulators of nuclear receptors | |
AU2003228283A1 (en) | Quinazolinone modulators of nuclear receptors | |
AU2003294264A1 (en) | Non-steroidal farnesoid x receptor modulators and methods for the use thereof | |
AU2001280597A1 (en) | Compositions for sustained release of analgesic agents, and methods of making and using the same | |
AU2004308299A1 (en) | Compounds and methods for development of Ret modulators | |
EP1536812A4 (en) | Methods for modulating activity of the fxr nuclear receptor | |
FI970328A (en) | Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors | |
TW200607798A (en) | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | |
AU2001279166A1 (en) | Network emulator for testing voip connections | |
NO20015272L (en) | Glucocorticoid receptor modulators | |
NO20030471D0 (en) | Carboxamide compounds and their use as antagonists for an 11CBY receptor | |
IL165990A0 (en) | Methods and compositions for modulating T helper (TH) cell development and function | |
WO2006047269A3 (en) | Pharmaceutical compositions | |
AU2001288277A1 (en) | Compounds and compositions for delivering active agents | |
NO20013318D0 (en) | Substituted 2-arylimino heterocyclic compounds and preparations containing them for use as progesterone receptor binding agents | |
WO2002064550A8 (en) | Glucocorticoid receptor modulators | |
WO2007024744A3 (en) | Heterocyclic carboxamide compounds as steroid nuclear receptor ligands | |
AU3196100A (en) | Heterocyclic sulfonamide derivatives | |
AU2001280470A1 (en) | Heterocyclic sulfonamide derivatives | |
AU2003213663A1 (en) | Methods and compositions for regulating adipogenesis | |
AU2003218824A1 (en) | Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them | |
AU2003258047A1 (en) | 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO(3,4-f)QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | |
AU3476599A (en) | Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists) | |
AU2003297408A1 (en) | Thiazole compounds as integrin receptor antagonists derivatives | |
NO20012939L (en) | Substituted heterocyclic asyl tripeptides for use as thrombin receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 107, 108, 117, 119, 120, 123, 164, 166, 175, 177, 194, 212, 315 AND 316, DESCRIPTION, REPLACED BY NEW PAGES 107, 108, 117, 119, 120, 123, 164, 166, 175, 177, 194, 212, 315 AND 316; AFTER RECTIFICATION OF OBVIOUS ERRORS AUTHORIZED BY THE INTERNATIONAL SEARCH AUTHORITY PAGES 107, 108, 117, 119, 120, 123, 164, 166, 175, 177, 194, 212, 315 ET 316, |
|
CFP | Corrected version of a pamphlet front page |
Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002806505 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002806505 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |